Calcium channel antagonists interfere with the mechanism of action of elastin-derived peptide VGVAPG in mouse cortical astrocytes in vitro.

Abstract

Elastin-derived peptides (EDPs) contain replications of the Val-Gly-Val-Ala-Pro-Gly (VGVAPG) hexapeptide. It has been described that the VGVAPG peptide induces reactive oxygen species (ROS) production in murine monocytes and astrocytes, human fibroblasts, and the human neuroblastoma (SH-SY5Y) cell line. To date, there is growing evidence that calcium channel blockers (CCBs) reduce oxidative stress and development of inflammation in the nervous system. Therefore, the aim of the present study was to evaluate the impact of such CCBs as Nifedipine, Verapamil, and MK-801 on the expression of peroxisome proliferator-activated receptor (Pparγ), i.e. ROS-related and inflammation-related proteins, in mouse astrocytes exposed in vitro to the VGVAPG peptide. The experiments showed that Nifedipine or MK-801 used in co-treatment with the VGVAPG peptide potentiated the effect of this peptide on the Pparγ level after the 24-h and 48-h treatment. Moreover, all studied compounds decreased the VGVAPG-induced caspase-1 activity in both time intervals. The data also showed that the VGVAPG peptide decreased the interleukin 1 beta (IL-1β) level in both studied time intervals. Upon a short-time exposure, the use of CCBs intensified the decrease in IL-1β stimulated by the VGVAPG peptide, opposite to the longer treatment. Moreover, the VGVAPG peptide decreased the IL-1βR1 level in both studied time intervals. After 24 h, Nifedipine and Verapamil potentiated the effect of the VGVAPG peptide. The VGVAPG peptide decreased the catalase (Cat) protein expression only after 24 h, whereas CCBs did not affect the expression of Cat induced by the VGVAPG peptide. The VGVAPG peptide increased the expression of the superoxide dismutase 1 (Sod1) protein. After 24 h of exposure, Nifedipine and Verapamil potentiated the increase in the Sod1 protein expression. Finally, our data showed that VGVAPG did not change the level of estradiol (E2) in the astrocytes. Interestingly, Nifedipine and Verapamil in co-treatment with VGVAPG increased the E2 level. Summarizing, it can be assumed that increased amounts of the VGVAPG during lifetime can play a certain role in calcium channel functioning in neurodegenerative diseases.

• Authors: Konrad A Szychowski, Bartosz Skóra, Anna Tabęcka-Łonczyńska
• Journal: Neurochemistry international (Neurochem Int) Vol. 159 Pg. 105405 (10 2022) ISSN: 1872-9754 [Electronic] England
• PMID: 35934159 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Chemical References

• Calcium Channel Blockers
• Oligopeptides
• PPAR gamma
• Peptides
• Reactive Oxygen Species
• Dizocilpine Maleate
• Elastin
• valyl-glycyl-valyl-alanyl-prolyl-glycine
• Verapamil
• Superoxide Dismutase-1
• Nifedipine

Topics

• Animals
• Astrocytes (metabolism)
• Calcium Channel Blockers (metabolism, pharmacology)
• Dizocilpine Maleate (pharmacology)
• Elastin (chemistry, metabolism, pharmacology)
• Humans
• Inflammation (metabolism)
• Mice
• Neuroblastoma (metabolism)
• Nifedipine (metabolism, pharmacology)
• Oligopeptides
• PPAR gamma (metabolism)
• Peptides (metabolism)
• Reactive Oxygen Species (metabolism)
• Superoxide Dismutase-1 (metabolism)
• Verapamil (metabolism, pharmacology)